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Introduction  
Prisons and jails in the U.S. bear a dispropor-
tionate share of the total United States popula-
tion with hepatitis C virus (HCV) infection.  The
primary source of HCV infections in the U.S. is
illegal injection drug use.1 Since drug offenders
make up 21% of state and 55% of federal prison
populations and even greater percentages of
offenders report past drug use 2, it is not sur-
prising that the prevalence of HCV infection in
correctional facilities (15% - 40%) is significant-
ly higher than in the general population
(1.8%).1,3 Additionally, it has been estimated
that at least a third of all HCV-infected persons
in the U.S. pass through a correctional facility in
any given year.4 These circumstances provide
a unique opportunity for correctional systems to
identify, treat, educate, and ultimately interrupt
the transmission of HCV by prisoners who are
released back into the community since HCV is
acquired primarily from risk behaviors occurring
outside of the correctional setting.5 Scarce
health care funding for HCV treatment within
corrections is one reason why this opportunity
has not been exploited.   With an estimated
400,000 HCV-infected offenders behind bars at
any one time, the potential cost of comprehen-
sive screening, testing, treatment, and preven-
tion programs would be enormous.3
Nonetheless correctional systems are assuming
responsibility for treating many of these inmates
who have chronic HCV infection since courts
have found that it is an Eighth Amendment vio-
lation to deny HCV treatment to an offender who
has significant liver disease that is amenable to
antiviral treatment.6 Consequently, correctional
systems are facing challenges in developing
evaluation and treatment guidelines that
address logistical and financial limitations to
treating HCV infections among offenders.   For
example, since continued HCV care for inmates
after release is generally not available, duration
of incarceration has been adopted as an exclu-
sionary criterion for treatment by many correc-
tional jurisdictions.  Likewise, among offenders
with chronic HCV infection and no medical or
psychiatric contraindications to treatment, ALT
levels may be used to decide who should be
considered for antiviral therapy because of the
geographical and security challenges of trans-
porting patients to a facility where liver biopsy
can be done.7 Logistically, using ALTs may
make sense; yet one large collaborative study
demonstrated that ALT levels lack adequate
sensitivity and specificity on which to base treat-
ment decisions  in the correctional setting or
elsewhere.8
Liver biopsy remains the gold standard in mak-
ing treatment decisions regarding HCV infec-
tion; and it should be emphasized that deferral
of treatment is appropriate and cost effective for
those with little or no evidence of fibrosis provid-
ed that appropriate follow up conducted periodi-
cally to assess disease progression.9 But there
is a general consensus that even the gold stan-
dard is not perfect.  First, liver biopsy is expen-
sive and associated with low, but predictable
rates of morbidity and mortality.10 Further, the
histopathological samples obtained by percuta-
neous liver biopsy are often not representative
of the overall condition of the liver or may not be
large enough to make an accurate diagnosis.11
Finally, the interpretation of fibrosis is dependent
upon the skill and experience of the pathologist
reading the biopsy specimen.12 For all of these
reasons, there has been a great deal of basic
and clinical research aimed at identifying nonin-
vasive markers of hepatic fibrosis that can be
used to accurately predict significant fibrosis for
patients with HCV infection as well as other con-
ditions associated with hepatic fibrosis.
Although many serum markers of hepatic fibro-
sis have been identified, none has been identi-
fied that can entirely replace the need for liver
biopsy.  
This article describes why and how The Texas
Department of Criminal Justice (TDCJ) incorpo-
rated one of these serum markers of hepatic
fibrosis, the AST Platelet Ratio Index (APRI),
into its HCV evaluation and treatment guideline. 
Serum Markers of Hepatic Fibrosis
Serum markers of hepatic fibrosis reflect the
state of fibrosis and fibrogenesis within the liver.
These markers can be divided into two groups:
Indirect and direct markers.  Indirect markers
include common clinical tests such as platelet
counts, serum transaminases, glutamyl
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Dear Correctional Colleagues,
The management of hepatitis C virus (HCV) was one those topics that was guaranteed to get
a room full of correctional health care professionals into uproarious debate.  Saddled with an
astoundingly high prevalence of HCV among inmates, prisons and jails have had to deal with
the cruel double edge of HCV treatment; therapy can be curative but is expensive, difficult to
tolerate and has disappointingly low rates of success.  The limitations of HCV therapy have
prompted many correctional systems to withhold or restrict this treatment.  Meanwhile, as HCV
therapy has become more commonplace in the free world and clinical studies make clear the
benefits of treatment, there has been increasing pressure for HCV therapy to be made widely
available to prisoners.
In response more correctional systems have come to embrace HCV therapy and have crafted
procedures and policies regarding the diagnosis and treatment of this infection.  Recently,
IDCR reported on the approach taken by prisons in Hawaii and in this issue we provide a
report by Dr. David Paar from Texas who describes an innovative strategy that system has
developed to identify patients who are most appropriate for HCV therapy while avoiding liver
biopsy.  In addition, Dr. Lester Wright shines a spotlight on a unique program in New York State
to maintain HCV therapy continuity following prison release.
As most of us are well aware, the threat of litigation has motivated the adoption of HCV ther-
apy in correctional systems in no small way. Dr. Joseph Paris, former Medical Director for the
Georgia Department of Corrections, in this issue provides his perspective on the legal pitfalls
of HCV management in a correctional setting.   
Over the past few years more of our inmates have obtained the opportunity to receive treat-
ment for their HCV and different systems, prisons (and even some jails) have devised their
own approaches to this infection.   Alas, the old HCV in corrections debate has died down only
to be replaced by other controversies - many of which you can be assured will be covered in
forthcoming issues of IDCR.
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit 
The University of North Carolina - Chapel Hill
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transpeptidase (GGT), and total bilirubin - all
of which measure hepatic function.  In con-
trast, the direct serum markers more accu-
rately reflect the complex process of fibro-
genesis.  Fibrogenesis is a dynamic process
characterized by deposition and degrada-
tion of the extracellular matrix (ECM) of the
liver by stellate and other fibrogenic cells
within the liver.  Many serum markers of
ECM remodeling are under investigation.  A
few examples are hyaluronic acid, metallo-
proteinases (MMPs), specific tissue
inhibitors of metalloproteinases (TIMPs),
macroglobulin, apolipoprotein A1, and hap-
toglobin.13,14
Many clinical studies have documented the
correlation between serum markers of
hepatic fibrosis with stage of fibrosis on liver
biopsy to determine which markers, or more
accurately, combinations of markers can
accurately predict insignificant fibrosis (F0,
F1), which does not require treatment, from
significant fibrosis (F2, F3, F4), which does
require treatment.15-21 See HCV 101 for an
explanation of the fibrosis staging score.22
Not all of these tests are directly comparable
because existing studies differ in their defin-
ition of fibrosis staging as well as in the pop-
ulation in which they have been validated.
Given these limitations, it can generally be
stated that using many of these tests,
approximately 50% of patients can be clas-
sified as having either insignificant fibrosis
or significant fibrosis obviating the need for
further evaluation by liver biopsy.  The other
50% of patients will require liver biopsy to
determine extent of fibrosis.  Of course,
even the best serum marker tests are not
100% accurate.  Thus the decision not to
biopsy based on a serum marker assay
alone is incorrect.  Other factors that might
be taken into account when assessing the
accuracy of a serum marker of fibrosis
include historical data such as alcohol
intake, physical examination findings such
as enlarged spleen, or laboratory data such
as prolonged coagulation times that suggest
that the serum marker assay is inaccurate.9
Table 1 lists and characterizes the serum
markers of hepatic fibrosis generally avail-
able to clinicians practicing in the U.S.  
APRI in the TDCJ
Until January 2007, the University of Texas
Medical Branch - Correctional Managed
Care (UTMB-CMC), which provides health
care to approximately 80% of offenders
incarcerated in the TDCJ, followed an HCV
treatment guideline that relied on hepatic
transaminase elevations rather than liver
biopsy to determine suitability for HCV treat-
ment.  This guideline was recently modified
after studies conducted within prisons sug-
gested that it was more cost effective to
base HCV treatment decisions on liver biop-
sies rather than on transaminase eleva-
tions.23 In addition, it was decided to incor-
porate a non-invasive marker of fibrosis into
the guideline in order to reduce the number
of biopsies needed for treatment decisions.  
The APRI score was selected because it is
a simple formula (AST divided by platelet
count) based on commonly ordered and
inexpensive laboratory tests and has been
prospectively validated, in part, with prison-
er liver biopsy specimens and laboratory
values at UTMB.20,24 In previous studies,
using lower and upper cut-off values of 0.42
and 1.2, respectively, the APRI accurately
classifies 60% of people with HCV as having
either insignificant fibrosis (F0, F1) or signif-
icant fibrosis (F2, F3, F4).20 In the other
40% of patients, percutaneous liver biopsy
must be used to assign stage of fibrosis in
order to make a treatment decision.   By
using the APRI, it was anticipated that the
number of biopsies performed on HCV pos-
itive offenders would be reduced by approx-
imately 50% in comparison to a guideline
that did not incorporate the APRI or other
serum marker of hepatic fibrosis.
The IDCR-O-Gram shows how the APRI has
been incorporated into the UTMB - CMC
HCV management guideline.  Because HCV
genotype II and III infections respond well to
a six month course of pegylated interferon
plus ribavirin, all genotype II and III patients
are considered potential candidates for ther-
apy regardless of APRI score.  This makes
sense from a public health view point as
well; eliminating these infections leads to a
decrease in the overall reservoir of infection.
All HIV/HCV co-infected patients are candi-
dates for treatment and receive a liver biop-
sy to aid in treatment decisions.  
Since this guideline was adopted, Snyder, et
al. 24 have published an algorithm in which
the APRI and the FIBROSpect II (see Table
1) are used to sequentially screen a
prospective cohort of patients undergoing
liver biopsy for evaluation of HCV infection.
The APRI was used as an initial screening
tool for the prediction of fibrosis.  The
FIBROSpect II was used to assess the
group of patients whose APRI score was
indeterminate.   Using this strategy the per-
centage of 93 prospectively assessed
patients whose fibrosis could be accurately
predicted, using liver biopsy as the stan-
dard, was 74.2 %.  This suggests that it may
be possible to combine these tests to further
reduce the number of biopsies necessary to
make accurate diagnosis of stage of fibrosis.
Summary
Correctional institutions are treating increas-
ing numbers of offenders with HCV infec-
tions.  Treatment guidelines can promote
cost effective means of evaluating and treat-
ing HCV infections through judicious appli-
cation of non-invasive means of assessing
fibrosis.  UTMB-CMC has incorporated the
APRI into its evaluation and treatment regi-
men and will assess its effectiveness in
ongoing quality assurance programs.
3
Continued on page 4
INCORPORATION OF THE AST PLATELET...
(continued from page 1)
September 2007        Vol. 9, Issue 19 visit IDCR online at www.IDCRonline.org
Table 1.  Serum Markers of Hepatic Fibrosis.  
CommentSerum Marker
Forn's Score
HCV -
FibroSURETM
FIBROSpect II®
HepaScore®
APRI
Fib-4
Ref.
14
15
16
17
18,
19
20
A model with a complicated, nonproprietary formula using age, GGT, platelet count, and cholesterol to select patients at very
low risk of significant fibrosis (F0, F1).  A score below 4.2 had a negative predictive value of 96% in excluding patients with
insignificant fibrosis (F0F1).  Approximately 50% of patients could be classified without biopsy using this model.  The model
did not perform as well in selecting patients with significant fibrosis (F2, F3, F4).
This is a proprietary test that combines O2 macroglobulin, haptoglobin, total bilirubin, apolipoprotein A1, GGT, and ALT with a
patient's age and gender in a patented algorithm to predict fibrosis and necroinflammatory activity.  A score of < 0.2 was able
to exclude patients with insignificant fibrosis (F0, F1) with a negative predictive value of 90% and a score of > 0.8 had a 90%
positive predictive value of significant fibrosis (F2, F3, F4).
This proprietary test uses hyaluronic acid, TIMP-1, and O2 macroglobulin in a patented algorithm to calculate a score that
predicts fibrosis.  Using a cut off value of 42, the test is 71.8 % and 55.1% sensitive at detecting F2, F3, F4 fibrosis and F0,
F1 fibrosis respectively.
This proprietary test uses O2 macroglobulin, hyaluronic acid, GGT, and total bilirubin along with age and sex in a patented
formula.  In an internal validation by Quest Diagnostics a score > 55 is 88% sensitive and 69% specific for the presence of
hepatic fibrosis (F2, F3, F4).
In the original paper, an APRI score of < 0.5 had an 86% negative predictive value of excluding significant fibrosis.  In a
refinement and prospective validation of the APRI at another center it was shown that in 60% of patients studied, an APRI
value < 0.42had a 93% negative predictive value in excluding F2, F3, F4 fibrosis and an APRI of > 1.2 had a 93% positive
predictive value of including this diagnosis.  Patients who fall in the indeterminate zone between 0.42 and 1.2 cannot be
accurately classified and require a live biopsy to stage fibrosis.
A relatively simple, nonproprietary calculation:  (age [year] x AST [U/L])/(platelets [109/L] x ALT [U/L]) that has been pro-
posed as an accurate marker of fibrosis in HIV HCV co-infected patients.
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Joseph E Paris, PhD, MD, FSCP, CCHP
Consultant
Disclsoures: Nothing to Disclose 
Introduction
Hepatitis C virus (HCV) infection is common
among the incarcerated and it is generally
agreed that inmates with risk factors for this
infection should be offered testing for
HCV.1-4 Such testing has been found to
identify high numbers of HCV-infected
inmates, but the role of correctional systems
in the management of the HCV-infected
inmate has been subject to considerable
debate within prisons and jails, the profes-
sional and lay press and the courts. What
follows is a description of the major legal
aspects of HCV management in prisons and
jails and a suggested set of rational
approaches to avoid litigation.
A rational HCV policy: Screening 
Given the high prevalence of HCV in cor-
rectional settings, correctional health care
systems large and small need to offer HCV
testing to all inmates reporting or evidencing
positive risk factors for infection and should
also have policies that permit inmates to
request HCV screening. Mandatory HCV
testing of inmates, like mandatory HIV test-
ing, may have unintended negative conse-
quences, such as discouraging testing and
risking stigmatization, and should be avoid-
ed.  
Inmates who are confirmed to be HCV -
infected should be counseled with respect
to transmission potential and to the risks
and benefits of HCV treatment.  All HCV-
infected persons should be offered vaccina-
tion for hepatitis A virus, hepatitis B virus
and be screened for HIV infection. 
A rational HCV policy: Staging 
Once active HCV infection is diagnosed,
assessment of HCV disease severity fol-
lows.  The goals of disease staging are two-
fold: to accurately assess the extent of liver
damage for the benefit of the patient and
physician and to aid in HCV treatment deci-
sion-making.  Severity of liver disease can
influence discussion of whether to initiate
HCV therapy and also be a factor when
deciding whether to continue or halt therapy
when treatment related toxicities develop.
A liver biopsy is often used to assess the
status of HCV patients although alternative,
non-invasive markers of liver disease are
being developed and put into practice (see
Main article). Depending on the liver archi-
tecture, a Grade and a Stage of liver pathol-
ogy can be assigned by a pathologist.
Grade is defined as a histologic assessment
of necro-inflammatory activity (not fibrosis).
The degree of fibrosis found is assigned a
Stage. Different systems exist to assign
these Grades and Stages numbers from 0
to 4 or from 0 to 6 (se HCV 101). The num-
bers have prognostic significance.5 
While there are challenges to obtaining liver
biopsies for inmates of some correctional
systems including the need to transport to
patients to outside medical facilities, the util-
ity of this procedure is largely now accept-
ed.  Further, testing inmates for HCV and/or
performing liver biopsies is not very expen-
sive when compared to the potential costs
of treating large numbers of HCV positive
inmates with IFN-based therapies and other
drugs.6
A rational HCV policy: Treatment 
In devising a rational HCV policy for either
large or small correctional systems, physi-
cians and managers need to have a clear
idea of the medical goals sought.      
Authorities agree that the goal of HCV treat-
ment is to achieve a Sustained Viral
Response (SVR).  SVR may not represent a
true "cure".  Rather, it may mark a cessation
of viral activity and suppression of viral repli-
cation for prolonged periods.  Cessation of
viral replication has been associated with
improvements in liver histology and
enzymes. Although early studies of patients
with SVR suggest possible lengthening of
survival, a final word on survival is not in. 
Further complicating matters is the unclear
natural history of HCV infection. This is one
of the most controversial and hotly debated
topics in hepatology today. There seems to
be two extreme positions. For some, HCV
infection is an indolent disease which may
take 20-30 years to claim the lives of
approximately 20% of those infected - espe-
cially if the patient drinks alcohol. Since
inmates generally cannot obtain alcohol
regularly, their liver disease would be more
likely to progress slowly.  Others feel that
the HCV virus is aggressive, causes rapid
liver disease progression (especially in
patients co-infected with HIV) and may be
fatal in 5 years or less. According to this way
of thinking, in order to avoid severe morbid-
ity and mortality patients must be treated as
soon as possible.
In a study of 123 HCV-infected patients who
did not receive HCV therapy, serial liver
biopsies showed that fibrosis scores pro-
gressed very slowly over the course of
years.5 The authors extrapolated these find-
ings to suggest that up to 50 years may
elapse from initial HCV infection to
advanced, potentially fatal cirrhosis of the
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liver. They concluded that the best predic-
tors of fibrosis were the extent of serum ALT
elevations and the degree of hepatocellular
necrosis and inflammation on liver biopsy.
Their conclusion: "Patients with normal ALT
and mild histology can safely defer treat-
ment" has been often cited by correctional
medical authorities formulating rather
restrictive inmate treatment eligibility poli-
cies.  
The impact of length of sentence prior to
treatment approval
A difficult question regarding inmate eligibil-
ity for IFN-based therapy is whether there is
enough time to complete such treatment.
The Federal Bureau of Prisons has led the
way with policies and guidelines that
required sufficient sentence time to com-
plete the treatment.  The rationale was
predicated on the fact that it is generally dif-
ficult to ensure continuation of IFN treat-
ment upon inmate release. An interruption
of a few weeks would cause the loss of ben-
efit of previously given treatments, with the
need to restart the treatment course from
the beginning and a risk that the treatment
would still be effective.
For Genotype 1 HCV (the most common in
U.S. prisoners) 48 weeks was and is the
recommended duration of IFN-based thera-
py. Since two, three, or more months may
be needed to complete initial evaluations,
only inmates with well over a year left in
their sentences would qualify for IFN-based
therapies.  In jails, the vast majority of
inmates are held for shorter periods.
Therefore, they would not generally be eligi-
ble for HCV therapy.  The exception would
be the few inmates sentenced to jail terms
of over a year. Unfortunately, some jail
physicians would assume that most inmates
are not be eligible and therefore do not initi-
ate testing, counseling, vaccination, and
other very necessary ministrations for any
inmates. 
In prisons, the situation was somewhat
clearer, because prisons house a number of
inmates serving very long sentences who
easily meet the length of sentence require-
ment. However, prisons also house sub-
stantial numbers of inmates with sentences
of five years or less. Because of overcrowd-
ing, early release of these prisoners may
occur at any time. In addition, many inmates
regularly appear before Parole Boards and
may unexpectedly be granted parole. It fol-
lows that, in some systems, state prisoners'
length of stay may be hard (if not impossi-
ble) to calculate. In order to make rational
decisions on IFN therapy, prison providers
must understand the system of inmate
release in use. 
Should HCV treatment be given by spe-
cialized consultants?
As knowledge on HCV became more
sophisticated, a number of Infectious
Diseases (ID) and Gastroenterologists (GI)
became HCV consultants. A major issue
evolved for correctional physicians
(Internists, Family Physicians) regarding
whether to treat their own HCV
inmate/patients or to refer them to special-
ists. Very few correctional Internists or
Family Physicians have the training and
expertise to perform their own liver biopsies.
While in principle therapies for HCV are not
that complex, they frequently require con-
comitant treatment with antidepressants,
erythropoietin, granulocyte stimulating fac-
tor, and other stimulants of the blood form-
ing organs. In many correctional systems, a
division of labor evolved where HCV con-
sultants would see the inmate/patients at
time of performance of liver biopsy, IFN
therapy initiation, and the management of
any serious side effects of therapy. Primary
care prison/jail physicians would follow the
patients closely and would refer them to the
consultants as clinically indicated. In a num-
ber of correctional systems, telemedicine
became a very useful tool for HCV consult
follow up. However, in this writer's experi-
ence, very few consultants would schedule
an inmate/patient for liver biopsy or IFN
treatment initiation unless they had seen the
patient in person at least once.
The concept of HCV Pre-Therapy
Checklist
At the beginning of this decade, a number of
large correctional system physician/man-
agers observed that physicians unfamiliar
with HCV management may initiate IFN-
based therapy for inmate/patients who were
poor candidates by virtue of coexisting
physical or mental health issues and adher-
ence to therapy issues, among other rea-
sons.  These incorrect startups by inexperi-
enced practitioners endangered patient
health and greatly increased costs.  For
these reasons, and following the leadership
of the Federal Bureau of Prisons Health
Services, several large systems developed
the concept of a Pre-Therapy Checklist.
This list enumerated the various evaluations
required for consideration of HCV treatment
and also listed all the medical/mental health
contraindications to IFN in a single sheet.
The Georgia Department of Corrections
(GDC) adopted this system in 2003.  At the
time, there were substantial benefits from
this policy.  Since pharmacists would not
issue IFN to an inmate unless the Pre-
Therapy Checklist was complete, the docu-
ment became a road map guiding the
workup.  Items were completed in a
sequence leading to liver biopsy.  A conse-
quence of the use of this system was that
Inmates refusing one or more items listed in
the Pre-Therapy Checklist were considered
to be refusing therapy, as treatment
required completion of the checklist evalua-
tions. 
However, the Pre-Therapy Checklist
approval-denial mechanism became a
major litigation target.  Although, intended
as a checklist (a method to ensure that all
necessary medical history and blood testing
was documented and fell within certain
parameters), inmates and plaintiff's attor-
neys have represented the checklist as a
remote clinical consultation and that the
approving physician was conducting a con-
sultation without the benefit of a physical
examination.  Such a misconception has
rendered the tool difficult to explain and
implement.  At this time, the author does not
recommend its use.
Discharge planning for inmates under-
going IFN therapy
As discussed above, unexpected releases
of inmates on IFN therapy may occur at any
time. If the inmate knows his or her future
county of residence, correctional health
care staff should be ready to coordinate with
the appropriate department of public health
or other center for continued care.   In this
writer's experience, however, very few
health deaprtments are set up to treat indi-
gent HCV patients. Major IFN manufactur-
ers  have created HCV Patient Assistance
Programs precisely for such patients to pro-
vide these medications to qualified patients.
Consequently, upon learning that a given
inmate on IFN may leave the institution,
staff should provide the inmate with health
record summaries and educate the inmate
on medication storage and administration
and the availability of patient care programs.
The first few weeks after release are a hec-
tic time. The ex-inmate may need time for
stabilizing his/her situation before being
able to seek medical services. Issuing the
exiting inmate 30 days of IFN-based med-
ications plus an appropriate supply of
syringes and needles is one way to ensure
continued treatment while community care
is being established.7 
Strategies for preventing legal troubles
This author has experienced a number of
legal cases related to HCV care of prison-
ers.  In a typical case, an inmate sued
because after the finding of Stage 2 fibrosis
on a liver biopsy and persistently normal
ALT levels his IFN treatment was deferred,
with continuing monitoring.  Another inmate
sued because he did not receive treatment.
His liver biopsy had showed cirrhosis.  He
had florid ascites and had repetitive GI
bleeding episodes.  Another inmate sued
because his IFN-based regimen had been
delayed one year. Although he was eventu-
ally treated, he did not achieve SVR.  His
claim was that perhaps the earlier treatment
would have increased his likelihood of
achieving SVR.
All of these inmates sued in Federal Court.
None has prevailed. Still, these cases are
time consuming, expensive to defend, and
disturbing to all practitioners involved. It
seems that HCV-related issues are like a
legal lightning rod. In the author's opinion,
as of 2007, the following so called "exclu-
sions from IFN therapy", still in use in many
jurisdictions, may be challenged in Court:
Exclusions due to ALT levels
Exclusions due to prior drug history
Exclusions due to psychiatric history
Exclusions due to time to serve
Exclusions due to co-infection with HIV
Exclusions due to liver cirrhosis
Exclusions due to previous treatment
With respect to persistently normal ALT lev-
els, there has been a stream of recent
papers showing that patients with persis-
tently normal ALT levels may have ongoing
histological deterioration, and that their
response to IFN-based therapies is almost
comparable to these patients with abnormal
ALT levels.8
Exclusions due to prior drug history have
Continued on page 6
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been used by certain systems.9 The author
estimates that these exclusions would fare
poorly in court today because such history
may be remote and not relevant to the
inmate's state of mind at time of treatment.
It appears that a positive random drug test-
ing, however, would be a much better indi-
cation of the likelihood of drug addiction
relapse after release. 
In a similar manner, exclusions solely due to
a positive, remote history of psychiatric
problems (including history of past suicide
attempts) would not be acceptable in court.
Instead, one would have to document that a
given inmate would not be a good candidate
for IFN-based therapies due to a contempo-
rary psychiatric condition (or suicidality) that
is not responding to appropriate treatment.
These patients would be better candidates
for therapy after psychiatric stabilization. 
Exclusions due to insufficient time to serve
had been generally acceptable to the courts
until a few years ago. The author has
observed that a number of similar cases
where he was involved as an expert witness
for the defense had to be settled. It seems
that defense attorneys, judges and juries
are migrating towards the idea that IFN-
based therapies should be started regard-
less of uncertainty of release date. The
rationale is that correctional practitioners
would not delay therapy for diabetes, can-
cer, anemia, and the like, solely based on
duration of sentence.  Treatment should be
offered, the thinking goes, together with
appropriate arrangements for continuity of
care should the sentence be too short.
Exclusions due to co-infection with HIV are
no longer acceptable. The available litera-
ture clearly shows that these co-infected
patients do achieve SVR (albeit less
often).10 Likewise, compensated liver cir-
rhosis is no longer a valid reason for exclu-
sion from treatment.11 
With respect to the difficult issue of re-treat-
ment, it seems that the non-correctional
HCV specialists are routinely offering re-
treatment to suitable candidates that failed
a less powerful regimen in the past. The
author believes that the standard of care in
corrections should reflect that of the com-
munity.
Conclusion
HCV management has proved to be one of
the more litigious areas of correctional
health care.  While litigation related to the
management of the HCV-infected inmate
cannot be completely eliminated it is evident
that in order to avoid legal action or to pre-
vail in litigation regarding HCV diagnosis
and therapy of inmates one needs to con-
struct a system of policies rooted in the
available evidence.  Such rational
approaches to the management of this
prevalent viral illness make for good sense
and good medicine.
The author was the Medical Director of the
Georgia Department of Corrections (GDC)
from 1996 to 2005. In collaboration with
specialists, he wrote the GDC HCV Policies,
versions of 1999, 2003, and 2004. These
are available in electronic form directly from
the author. Requests should be addressed
to joeparis@pol.net. 
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IDCR-O-GRAM: TEXAS DEPARTMENT OF CRIMINAL JUSTICE HCV ASSESSMENT ALGORITHM
Offender identified as HCV posi-
tive during medical evaluation.
Calculate APRI Score.
APRI > 1.2
-Patient likely has F2, F3, F4 fibrosis and will be treated unless there are medical contraindi
cations including decompensated cirrhosis.
-If there are signs of portal hypertension, patients have upper endoscopy prior to initiation of
anti-HCV therapy, to assess for varices and banding if indicated.
APRI Between 0.42 and 1.2
-Patient falls into the indeterminate range and fibrosis must be assessed with percutaneous
liver biopsy.
-Following biopsy, patients with F2, F3, F4
fibrosis are offered combination therapy with pegylated interferon + ribavirin.
-Treatment is deferred in patients with F0, F1 fibrosis unless other factors suggest that treat
ment is indicated.
APRI < 0.42
-Patient most likely has insignificant fibrosis (F0, F1) and treatment can be safely deferred.
-Follow APRI yearly or more frequently.
-Refer for consideration for liver biopsy if historical, clinical, or lab data suggest that APRI is
inaccurate.
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HCV 101
Metavir Scoring System
Stage Amount of Scarring
0 No Scarring
1 Minimal Scarring
2 Scarring has occurred and extends beyond the areas of the liver that contain blood vessels
3 Bridging Fibrosis is spreading and connecting to other areas that contain fibrosis
4 Cirrhosis or advanced scarring of the liver
DISEASE BURDEN FOR HEPATITIS-C IN THE UNITED STATES
2005 2004 2003 2002 2001
Number of Acute Clinical Cases Reported No Data No Data No Data No Data No Data
Estimated Number of Acute Clinical Cases 3,200 4,200 4,500 4,800 3,900
Estimated Number of New Infections Current 20,000 26,000 28,000 29,000 24,000
Historical Mean Min Max
67,000 36,000 179,000
232,000 180,000 291,000
Number of Persons with Chronic Infections 3.2 Million Persons
Estimated Annual Number of Chronic Liver Diseases Deaths 8,000-10,000
Perecent Ever Infected 1.60%
HCV incidence peaked in the late 1980s but has declined since with the screening of blood and blood products for the virus.
Source: CDC.2006
Hepatitis C Virus  - Source: CDC
HIV Therapy, Management &
Emerging Treatment Options
Live Satellite Video conference &
Webcast
October 3, 2007
12:30-2:30 p.m. EST
Visit: www.amc.edu/hivconference
518.262.4674 or
ybarraj@mail.amc.edu
Tuberculosis Program Manager's
Workshop
Newark, NJ
October 3, 2007
Visit: www.umdnj.edu/globaltb/cours-
es/tbworkshop.htm
45th Annual Meeting of the
Infectious Diseases Society of
America 
San Diego, CA
October 4, 2007
Visit:
www.idsociety.org/Meetingshome.aspx
?id=238
National Conference on
Correctional Health Care
Nashville, TN
October 13-17
Visit: http://www.ncchc.org/education/
national2007.html
2007 Annual Conference: Medicine
in the Face of Addiction
Society of Correctional Physicians (SCP)
October 14, 2007
Nashville, TN
Visit: http://www.corrdocs.org/frame-
work.php?pagetype=educonference&b
gn=1
15th Annual HIV/AIDS Update and
Border Health Summit
South Padre Island, TX 
24 to 26 October, 2007
Visit: http://www.valleyaids.org
The Liver Meeting 2007
58th Annual Meeting of the
American Association for the Study
of Liver Diseases
Boston, MA
November 2-6, 2007
Visit: https://www.aasld.org/eweb/
DynamicPage.aspx?webcode=07am
2007 United States Conference on
AIDS (USCA)
Palm Springs, CA
November 7-10, 2007
Visit: http://www.cdcnpin.org/scripts/
display/confdisplay.asp?confnbr=6149
AIDS in Culture IV: Explorations in
the Cultural History of AIDS
Mexico City
December 9-13, 2007
Visit: www.aidsinculture.org
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Tattooing in prisons - Not such a pretty picture
Tattoos have recently grown in popularity; recent esti-
mates assert that 10% to 16% of all U.S. adolescents
between the ages of 12 and 18 have at least one tat-
too.  As the prevalence of tattoos increases, so does
the risk of transmitting blood borne viruses (BBVs).
Recent case studies in prisons have linked unsafe tat-
tooing practices with HIV and hepatitis C virus (HCV)
infection in persons with no prior history of intravenous
drug use (IDU).  Although tattooing is prohibited in most
prisons, it is still a relatively common practice in most
correctional facilities today and is often conducted with-
out the use of clean needles and unused ink.
Hellard et al. conducted a cross-sectional survey of tat-
too and drug use history, along with HCV status, across
the five largest correctional facilities in Victoria,
Australia.  The study surveyed 642 inmates in total, 133
of whom were female.  A total of 449 prisoners (70%)
reported having at least one tattoo.  Of this group, 156
of inmates (35%) claimed to have been tattooed while
in prison, while another 26 individuals (6%) reported to
have been tattooed while in a juvenile detention facility.
A significant portion of inmates who had received tat-
toos outside of prison said they had done so through
the use of a nonprofessional tattoo artist.  The study
also demonstrated that prisoners who have a history of
IDU were more likely to have at least one tattoo and
were also more likely to have acquired a tattoo in
prison.  
Prisoners who were tattooed in prison had a signifi-
cantly higher risk of HCV-infection, even after adjusting
for IDU history, tattooing outside of prison, body pierc-
ing, and length of time in prison.  These findings raise
questions as to whether or not correctional facilities
should provide safer tattooing alternatives for incarcer-
ated persons such as the use of professional tattoo
artists and providing sterile tattooing equipment and
training to inmates. 
Tattooing in prisons-Not such a pretty picture.  Hellard,
M et al.  American Journal of Infection Control.
2006;35:477-80.
Project ECHO: Linking University Specialists with
Rural and Prison-Based Clinicians to Improve Care
for People with Chronic Hepatitis C in New Mexico
Specialists at the University of New Mexico School of
Medicine have begun collaborating with rural clinicians,
the Indian Health Service, and prisons in an effort to
improve the quality and accessibility of healthcare for
New Mexicans living with HCV.  The effort, named the
Project Extension for Community Healthcare Outcomes
Project (Project ECHO), seeks to use telemedicine and
distance-learning methods to discuss HCV case stud-
ies in patients at rural clinics.  Project ECHO is
designed to share the knowledge of HCV specialists
with primary-care physicians, an endeavor of great
importance given that nearly all of the counties in New
Mexico are listed as medically underserved and almost
half are considered to have health professional short-
ages.  Although an estimated 32,000 New Mexicans
are currently living with HCV, infectious disease spe-
cialists, gastroenterologists, and hepatologists with
experience in HCV treatment are few and far between.
As such, Project ECHO has used teleconferencing and
videoconferencing; internet-based assessment tools;
online presentations; and telephone, fax, and e-mail
communications to connect specialists with health care
providers across New Mexico.  Project ECHO partner
organizations, which are recruited through statewide
health care conferences, conduct a one day training
workshop for clinicians, after which clinicians shadow
ECHO team members in the University of New Mexico
HCV Clinic.
Since Project ECHO's inception in June 2003, 173 clin-
ics have been conducted and a total of 1,843 disease-
management case studies have been presented.
Moreover, health care providers in New Mexico have
earned 2,997 hours of continuing education credits and
390 hours of on-site training through this project.  In this
way, Project ECHO has been an extreme success and
is now being considered as a model of how to train pri-
mary-care physicians in providing quality care for other
chronic medical conditions.  Satellite ECHO projects
are now underway in other parts of New Mexico and
cover such areas as substance abuse disorders,
rheumatology, and mental health disorders.  The pro-
ject's founders are hopeful that ECHO team's approach
to strengthening the abilities of health care providers
could be implemented in developing countries with a
high prevalence of disease and limited health care
resources.
Project ECHO: Linking University Specialists with Rural
and Prison-Based Clinicians to Improve Care for
People with Chronic Hepatitis C in New Mexico.  Arora,
S. et al. Public Health Reports. 2007;122:74-77.
Promoting HCV Treatment Completion for Prison
Inmates: New York State's Hepatitis C Continuity
Program
This study sought to overcome some of the major bar-
riers in providing HCV treatment to incarcerated per-
sons in New York.  In particular, Klein et al. focused
their attention on how to best maintain continuity of
HCV antiviral treatment for inmates, regardless of their
length of stay in correctional facilities.  Many correc-
tional systems, including the New York State
Department of Corrections Services (DOCS), have poli-
cies that do not allow for the initiation of HCV antiviral
treatment for patients with limited time left in their sen-
tence as continuation of therapy post-release was not
assured.  The Hepatitis C Continuity Program was
established in an effort to allow inmates to be treated
for HCV infection while in prison, regardless of their
length of stay in the correctional setting, and to contin-
ue treatment through a community-based health care
partner after their release.  
The Program used the combined efforts of the DOCS,
the New York State Department of Health (DOH), the
New York City public hospital system, and the Health
and Hospitals Corporation (HHC) to establish connec-
tions between the correctional setting and community
health care providers and social workers, as well as
establish protocols for incorporating releasees into
community health care settings.  The DOCS manages
most prerelease activities, including scheduling an ini-
tial post-release appointment and ensuring that antivi-
ral drugs are given to each inmate upon their release.
Hospital staff members work with parole officers in
making further all medical appointments with the
releasee.
Twenty-one health care facilities in New York City now
accept inmates and releasees for HCV monoinfection
or HCV/HIV coinfection treatment.  The urban and sub-
urban locations of these facilities are such that they will
be geographically accessible to an estimated 87.1% of
releases being treated for HCV.  The Hepatitis C
Continuity Program demonstrates that it is possible to
initiate HCV treatment for prisoners, regardless of their
length of stay in prison.  While it is perhaps too soon to
evaluate the effectiveness of the Program, it is clear
that both the individual releasees and society as a
whole stand to benefit from this program's success.
Promoting HCV Treatment Completion for Prison
Inmates: New York State's Hepatitis C Continuity
Program. Klein, S. et al. Public Health Reports.
2007;122:83-88.
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